News

GMO acreage reaches new high
Enlarge image

BusinessEUSpainGermanyPoland

GMO acreage reaches new high

21.02.2013 - Global acreage of biotech crops have increased by 6% last year. Europe contributes only 0.075%.

Brussels/Manila - Genetically modified (GM) soybeans, maize, cotton and rapeseed were planted on 170.3 million hectares last year, according to figures from the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). However, the adoption of biotech crops has become slower. After double digit growth rates three years ago, this year the cultivation area increased only by 6 percent or 10.3 million hectares compared to 2011. 

However, Europe remains a minor player in the growing market for GMOs due to public hostility to GMOs. The EU countries grew 129,071 hectares of Bt maize, about 14,000 hectares more than in 2011. Spain remained the leading EU country for GMO acreage with 116,306 hectares in 2012. Poland discontinued the planting of biotech maize.  The US (69.5m ha, +0.7%), Brazil (36.6m ha, +20,8%), Argentina (23.9m ha, +0,8%), Canada (11.6m ha, +11,5), and India (10.6m ha, +1,8%) were the leading GMO producers. Global Adoption of GM soybeans (+8%), cotton (+7%), maize (+4%), and rapeseed (+5%) increased as compared to 2011.  

"There is one principal and overwhelming reason that underpins the trust and confidence of farmers in biotechnology: biotech crops deliver substantial, and sustainable, socio-economic and environmental benefits," stressed ISAAA chief Clive James. In fact, German BASF and Monsanto both filed for US approval of the first drought-tolerant crop last year. However, the US Department of Agriculture recently delayed the approval of new herbicide-tolerant GMOs because weeds are becoming more and more resistant to the herbicide Glyphosate, which is marketed together with Glyphosate-tolerant GMOs since 1996.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/gmo-acreage-reaches-new-high.html

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%

FLOP

  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015